ERBB2 and breast carcinoma: Among the 15 patients with brain metastases from HER2‐positive breast cancer, the T‐DXd intracranial response rate was 73.3% (11/15 cases), the clinical benefit rate (CBR) was 86.7% (13/15 cases), and the median PFS was 14 months [13].